Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Single Photon Emission Computed Tomography (SPECT) with DaTscan (SPECT-DaTscan) and CSF biomarkers (CLEM)

Method of Measurement (Pre-analytical Tools)
Imaging
CSF
Biomarker Measured
Unknown
Use
Prognostic
Predictive
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

To identify the biomarkers (MRI, SPECT-DaTscan® and CSF), and their combination, that are the most predictive of functional disability in elderly presenting with a progressive cognitive decline related to AD, DLB, VD and all mixed patterns.

Target Population/ Population Being Studied

Patients meeting diagnosis criteria for dementia due to Alzheimer's disease, vascular dementia, Lewy body disease, and patients presenting with mixed signs and symptoms suggesting a combination of these diagnosis

Length of Current Trial
2 years
Number of Trial Participants

214

Estimated Trial Completion
October 2020
What is Required from Patients

entering an fMRI machine (can induce claustrophobia), SPECT scan, Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

Single-photon emission computed tomography machine, MRI machine, technicines, physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Hospices Civils de Lyon

“Co-LEsions in Alzheimer Disease and Related Disorders (CLEM).” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT02052947?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=5&rank=44